

## Financial Highlights

(Billions of yen)

		FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Estimate FY2013 (Forecast as of Nov 2013)
Net sales	(Billions of yen)	955.9	1,084.3	1,127.6	1,154.6	1,218.1	892.6	1,077.6	1,435.0
	YoY	3.0%	13.4%	4.0%	2.4%	5.5%	1.3%	20.7%	17.8%
Operating income	(Billions of yen)	91.5	98.5	126.3	148.7	169.7	131.4	185.5	215.0
	YoY	-22.6%	7.6%	28.2%	17.7%	14.1%	-1.3%	41.2%	26.7%
Ordinary income	(Billions of yen)	96.1	109.1	128.4	152.1	184.5	140.8	203.0	225.0
	YoY	-22.6%	13.5%	17.7%	18.5%	21.3%	4.4%	44.2%	22.0%
Net income	(Billions of yen)	47.1	67.4	82.4	92.2	122.4	91.2	142.8	155.0
	YoY	-23.9%	43.2%	22.1%	11.9%	32.8%	2.9%	56.6%	26.6%
R&D expenses	(Billions of yen)	135.9	151.8	164.7	159.2	192.4	116.4	166.0	220.0
	YoY	33.5%	11.7%	8.4%	-3.3%	20.8%	1.2%	42.6%	14.4%
Overseas net sales	(Billions of yen)	395.0	525.5	552.5	579.7	622.7	434.2	590.1	808.0
	% of net sales	41.3%	48.4%	49.0%	50.2%	51.1%	48.6%	54.8%	56.3%

(Yen)

Exchange rate	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 3Q	FY2013 3Q	Estimate FY2013 (Forecast as of Nov 2013)
US\$	91.03	92.10	87.79	79.79	79.80	79.38	96.83	97.00
Euro	127.96	132.00	116.27	111.12	102.55	101.71	127.47	128.00

(Billions of yen)

Selling, general and administrative expenses	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Estimate FY2013 (Forecast as of Nov 2013)
Selling, general and administrative expenses	541.8	629.2	622.3	616.6	654.6	466.0	563.1	780.0
(% of net sales)	56.7%	58.0%	55.2%	53.4%	53.7%	52.2%	52.3%	54.4%
Promotion expenses	158.3	198.7	179.6	174.4	156.2	122.9	125.4	
Personnel expenses (including reserves)	85.7	96.7	97.9	99.8	103.7	76.2	90.0	
Advertising expenses	30.1	33.2	28.9	25.1	29.5	23.8	27.5	
Research and development expenses	135.9	151.8	164.7	159.2	192.4	116.4	166.0	220.0
(% of net sales)	14.2%	14.0%	14.6%	13.8%	15.8%	13.0%	15.4%	15.3%
R&D expenses of pharmaceuticals	131.9	141.6	153.4	149.3	183.5	109.9	159.9	210.0

(Billions of yen)

Capital expenditures	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Estimate FY2013 (Forecast as of Nov 2013)
Capital expenditures	63.4	62.5	44.8	43.3	63.3	38.4	148.2	72.0

Capital expenditures of FY2013 1-3Q includes tangible and intangible fixed assets of Claris Otsuka and Astex Pharmaceuticals that will be consolidated in FY

(Billions of yen)

Depreciation	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Estimate FY2013 (Forecast as of Nov 2013)
Depreciation	40.3	46.6	48.1	48.1	45.5	33.6	35.6	46.0

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Consolidated sales	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>1,218.1</b>	<b>892.6</b>	<b>1,077.6</b>	<b>20.7%</b>
Pharmaceutical business	651.7	715.9	751.1	782.2	850.9	606.7	757.8	24.9%
Japan	319.0	312.4	319.9	326.5	351.8	261.9	283.7	8.3%
North America	282.9	334.7	349.0	361.1	389.0	271.3	379.1	39.7%
Others	49.9	68.8	82.2	94.7	110.0	73.5	95.0	29.3%
Nutraceutical business	217.9	247.0	256.4	251.3	246.9	192.3	216.5	12.6%
Japan	163.9	142.6	154.1	147.4	142.3	117.5	121.6	3.5%
North America	38.8	47.1	46.8	45.8	49.8	34.2	39.2	14.6%
Others	15.2	57.3	55.6	58.1	54.8	40.6	55.6	37.1%
Consumer products business	51.9	50.1	47.1	48.0	45.2	36.8	34.6	-5.9%
Japan	45.7	44.1	40.9	42.0	39.2	32.0	29.0	-9.3%
North America	6.2	5.4	5.5	5.4	5.4	4.3	5.4	26.0%
Others	0.0	0.6	0.7	0.6	0.6	0.6	0.3	-54.6%
Other business	34.4	71.3	72.9	73.1	75.0	56.9	68.7	20.9%
Japan	32.4	59.7	60.1	59.1	62.0	47.0	53.1	13.1%
North America	0.4	1.3	1.4	1.3	1.4	1.0	1.6	56.4%
Others	1.6	10.4	11.4	12.7	11.6	8.8	14.0	58.1%
Japan -total	560.9	558.8	575.1	574.9	595.3	458.3	487.5	6.4%
North America - total	328.3	388.4	402.7	413.5	445.7	310.8	425.3	36.8%
Others - total	66.7	137.1	149.8	166.2	177.1	123.4	164.9	33.6%
Overseas net sales	395.0	525.5	552.5	579.7	622.7	434.2	590.1	35.9%
Overseas net sales ratio	41.3%	48.4%	49.0%	50.2%	51.1%	48.6%	54.8%	

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Net Sales and Operating Income by Geographical and Business Segment

### (1) Geographical segment

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Net sales	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>1,218.1</b>	<b>892.6</b>	<b>1,077.6</b>	<b>20.7%</b>
Japan*	689.0	709.4	745.2	779.1	842.5	607.7	745.4	22.6%
North America*	315.0	406.2	426.0	437.5	474.1	333.7	461.4	38.3%
Others*	55.6	121.6	132.5	142.4	138.2	102.5	149.6	46.0%
Eliminations/corporate	-103.6	-152.8	-176.2	-204.4	-236.7	-151.4	-278.7	

\*Intersegment sales are included.

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Operating income	<b>91.5</b>	<b>98.5</b>	<b>126.3</b>	<b>148.7</b>	<b>169.7</b>	<b>131.4</b>	<b>185.5</b>	<b>41.2%</b>
Japan	73.8	86.5	106.3	142.5	160.8	119.1	185.9	56.1%
North America	9.9	11.3	12.2	14.4	16.2	6.3	-5.4	-185.9%
Others	5.2	8.4	6.8	3.7	6.4	6.1	5.8	-4.5%
Eliminations/corporate	2.6	-7.7	1.0	-12.0	-13.8	-0.1	-0.8	

### (2) Business segment

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Net sales	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>1,218.1</b>	<b>892.6</b>	<b>1,077.6</b>	<b>20.7%</b>
Pharmaceutical business*	652.2	715.9	751.1	782.2	850.9	606.7	757.8	24.9%
Nutraceutical business*	219.2	248.8	258.7	254.8	251.8	195.8	221.0	12.9%
Consumer products business*	52.1	51.1	47.9	49.2	46.9	37.9	34.7	-8.3%
Other business*	60.1	105.1	106.9	108.6	111.7	85.4	98.0	14.8%
Eliminations/corporate	-27.6	-36.6	-37.0	-40.3	-43.1	-33.1	-33.9	

\*Intersegment sales are included.

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Operating income	<b>91.5</b>	<b>98.5</b>	<b>126.3</b>	<b>148.7</b>	<b>169.7</b>	<b>131.4</b>	<b>185.5</b>	<b>41.2%</b>
Pharmaceutical business	133.6	132.9	142.8	168.5	187.9	141.7	193.5	36.5%
Nutraceutical business	-5.2	2.3	18.4	22.1	21.4	17.3	20.4	18.1%
Consumer products business	-3.7	-8.4	-2.2	-2.3	-2.4	-1.4	-1.5	-
Other business	2.3	4.4	4.4	1.9	3.9	4.3	6.0	41.5%
Eliminations/corporate	-35.5	-32.7	-37.1	-41.6	-41.0	-30.4	-32.9	

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Product sales - Pharmaceutical business

(Billions of yen)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change	Estimate FY2013 (Forecast as of Nov 2013)
Antipsychotic agent <i>ABILIFY</i>	Otsuka Pharmaceutical	297.1	374.5	392.6	411.6	438.5	309.8	409.2	32.1%	560.0
North America		237.2	305.6	308.3	316.1	336.1	236.6	321.7	35.9%	443.0
<US\$ million>		<2,606>	<3,303>	<3,512>	<3,960>	<4,208>	<2,979>	<3,319>	11.4%	<4,565>
Japan		13.2	18.8	23.0	24.8	28.6	22.2	25.0	12.4%	33.0
Others		46.7	50.1	61.2	70.7	73.9	51.0	62.5	22.6%	84.0
Anti-platelet agent <i>Pletal/Pletal</i>	Otsuka Pharmaceutical	46.6	51.5	53.2	50.3	45.8	35.7	35.1	-1.8%	42.5
Japan		42.1	45.4	46.5	44.1	40.1	31.3	29.4	-6.1%	35.0
Others		4.5	6.1	6.7	6.2	5.7	4.4	5.6	29.3%	7.5
Anti-gastritis and anti-gastric ulcer agent <i>Mucosta</i>	Otsuka Pharmaceutical	38.3	37.1	30.7	28.7	23.0	18.1	17.2	-5.0%	21.5
Japan		36.2	34.5	27.8	26.0	20.5	16.2	14.9	-8.3%	18.5
Others		2.1	2.6	2.9	2.7	2.5	1.9	2.4	23.3%	3.0
Anti-metabolite <i>TS-1</i>	Taiho Pharmaceutical	46.0	37.3	37.1	36.5	37.0	28.5	30.6	7.6%	40.0
Anti-metabolite <i>UFT</i>	Taiho Pharmaceutical	25.6	18.3	15.7	12.9	11.2	8.8	7.5	-14.8%	10.0
Reduced folic acid formulation <i>Uzel</i>	Taiho Pharmaceutical	17.7	15.2	14.1	12.7	13.2	10.2	9.2	-9.6%	12.0
Urinary incontinence / frequency treatment <i>P4 (BUP-4)</i>	Taiho Pharmaceutical	10.0	7.6	7.0	6.3	5.6	4.5	3.8	-15.6%	5.5
Oral nutrient for liver failure <i>Aminoleban EN</i>	Otsuka Pharmaceutical	6.2	6.4	6.5	6.1	5.7	4.5	4.3	-3.4%	5.5
Bronchodilator <i>Meptin</i>	Otsuka Pharmaceutical	6.1	5.9	6.1	5.7	5.2	4.1	3.9	-5.7%	5.0
H <sub>2</sub> -receptor antagonist <i>Protecadin</i>	Taiho Pharmaceutical	6.0	5.1	5.8	6.3	5.9	4.7	4.0	-14.9%	5.5
5-HT <sub>3</sub> receptor antagonist <i>Aloxi</i>	Taiho Pharmaceutical			4.3	7.9	10.0	7.7	8.4	9.0%	11.0
Antineoplastic <i>Abraxane</i>	Taiho Pharmaceutical			1.1	3.2	3.7	2.8	6.5	131.0%	8.5
Antiepileptic <i>E Keppra</i>	Otsuka Pharmaceutical			0.8	4.8	10.5	7.9	11.5	44.9%	15.0
V <sub>2</sub> -vasopressin receptor antagonist <i>Samsca</i>	Otsuka Pharmaceutical		0.6	3.2	6.7	12.8	8.8	15.2	72.9%	20.5
Anticancer <i>SPRYCEL</i> (collaboration with BMS)	Otsuka Pharmaceutical		2.0	8.0	7.6	12.0	6.4	20.0	210.9%	26.0
Antibiotic <i>Zosyn/Tazocin</i> (bulk supply)	Taiho Pharmaceutical	12.2	11.2	11.2	10.7	12.4	9.1	9.7	7.0%	13.0
Diagnostics -total	Otsuka Pharmaceutical	5.3	8.2	6.6	7.9	8.8	5.2	7.5	42.8%	11.0
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	89.8	92.9	96.8	96.0	96.4	75.2	80.0	6.3%	101.5
Japan		82.4	83.0	87.6	88.6	88.8	69.6	72.2	3.7%	90.0
Others		7.4	9.9	9.2	7.4	7.6	5.6	7.8	39.3%	11.5
Pharmaceutical business -total (excluding exports)	Japan	319.0	312.4	319.9	326.5	351.8	261.9	283.7	8.3%	369.0
Pharmaceutical business -total	Total	651.7	715.9	751.1	782.2	850.9	606.7	757.8	24.9%	1,015.0

\* The segment classification of quasi-drugs and nutritional products was changed from the pharmaceutical business to the nutraceutical business in July 2008.

\* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of the change in fiscal year end.

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

**Product sales - Nutraceutical business**

(10 thousand cases)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		2,987	2,624	3,234	2,912	2,709	2,263	2,430	7.4%
Overseas		1,650	1,884	1,597	1,963	2,151	1,619	2,083	28.7%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		303	187	113	100	88	71	91	27.7%
Overseas		40	46	28	20	12	9	12	32.6%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,114	1,042	1,051	1,081	1,067	871	898	3.0%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	387	396	392	351	335	264	262	-0.8%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	495	428	484	532	489	410	326	-20.5%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,928	1,591	1,571	1,579	1,588	1,314	1,228	-6.6%

\* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of a change in the fiscal year end.

\* Overseas sales include sales of consolidated subsidiaries only.

**Product sales - Consumer products business**

(10 thousand cases)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	1,102	840	674	679	567	460	475	3.2%
<i>NESCAFE</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	818	676	680	616	536	420	350	-16.6%
<i>Match</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	321	332	371	451	521	439	418	-4.8%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	361	390	267	317	300	242	211	-12.9%

**Product sales - Other business**

(Billions of yen)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-3Q	FY2013 1-3Q	Change
Functional chemicals	Otsuka Chemical	27.0	23.2	26.3	27.9	26.6	20.2	24.9	23.3%
Fine chemicals	Otsuka Chemical	14.6	13.7	12.4	9.3	10.2	7.6	7.1	-6.7%

## Otsuka Group – Pipeline Information

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<b>Central nervous system</b>						
OPC-14597 <ABILIFY*> <Abilify Maintena*>:Depot injection	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot injection	EU JP	Approved Phase III
				Autism / Oral	JP	Phase III
				Tourette's disorder / Once-weekly Tablet	US	Phase III
				Bipolar I / Depot injection	JP, US, EU	Phase III
L059 <EKEPPRA*>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral	JP	Phase III
				Epilepsy (partial onset seizures) / injection	JP	Filed
				Epilepsy (partial onset seizures/mono therapy) / Oral	JP	Phase III
OPC-34712	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US, EU	Phase III
				Schizophrenia / Oral	JP, US, EU	Phase III
				ADHD (Adults) / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III**
Lu AE58054		Lundbeck	Selective serotonin 5-HT <sub>2</sub> receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "\*" are the names used outside Japan.

Note 3: started on January in US and EU

<Events after Dec 31, 2013>

Aripiprazole/depot injection / schizophrenia: filed on January in Japan

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<b>Anti-cancer and cancer-supportive care</b>						
ABI-007 <Abraxane>	paclitaxel protein-bound particles for injectable suspension	Celgene	Anti-cancer (nanoparticle)	Pancreatic cancer / Injection	JP	Phase I / II
S-1 <TS-1> Japan, Korea <TEYSUNO*> EU <TS-ONE*> Singapore <愛斯方*> China <愛斯萬*> Taiwan	tegafur, gimeracil, oteracil potassium	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Gastric cancer / Oral Uterocervical cancer / Oral Hepatocellular carcinoma / Oral Renal cell carcinoma / Oral	US JP, Asia JP JP	Phase III Phase III Phase III Phase II
TSU-68	orantinib	(Sugen)	Anti-cancer (Molecular-targeted drug)	Hepatocellular carcinoma / Oral	JP, Asia	Phase III
TAS-102	trifluridine, tipiracil hydrochloride	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral SCLC / Oral	JP JP, US, EU, Asia JP, EU	Filed Phase III Phase II
TAS-118	tegafur, gimeracil, oteracil potassium, calcium folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
<SPRYCEL>	dasatinib	BMS	Anti-cancer	Pancreatic cancer / Oral	US, EU	Phase II
SGL-110		Astex	Anti-cancer	Ovarian cancer / Injection Liver cancer / Injection Acute myeloid leukemia, Myelodysplastic syndrome / Injection	US, EU US, EU US	Phase II Phase II Phase II
AT13387		Astex	Anti-cancer	Prostate cancer / Injection NSCLC / Injection	US, EU US, EU	Phase II Phase II
AT7519		Astex	Anti-cancer	Multiple myeloma / Injection	US	Phase II
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Phase II
TAS-106		Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Solid tumors / Injection	US	Phase I / II
OPB-31121		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	JP, US, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "\*" are the names used outside Japan.

Otsuka Group – Pipeline Information

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
<b>Cardiovascular</b>						
OPC-41061 <SAMSCA*>	tolvaptan	Otsuka Pharmaceutical	Vasopressin V <sub>2</sub> -receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	JP, US, EU	Filed**
				Cardiac edema / Oral	Asia	Phase III
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
<b>Other areas</b>						
YP-18 <ZOSYN*>	tazobactam sodium · piperacillin sodium	Taiho Pharmaceutical	Antibiotic agent	Febrile neutropenia / Injection	JP	Phase III
TAC-202	bilastine	Faes Farma	Histamine H <sub>1</sub> antagonist	Allergic rhinitis / Oral	JP	Phase II
OPC-67683	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	JP, EU, US, EU	Filed Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPB-2045G	gluconate olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Phase III
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
ACU-4429	emixustat hydrochloride	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II b / III
OPA-6566		Otsuka Pharmaceutical	Adenosine A <sub>2a</sub> receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase I
<b>Diagnostics</b>						
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II
ODK-1201-01	Major bcr-abl mRNA kit	Otsuka Pharmaceutical	Diagnostic aid for CML	For the diagnosis of bcr-abl / In-vitro diagnostic agent	JP	Filed

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "\*" are the names used outside Japan.

Note 3: \*\* Otsuka received complete response letter from FDA in August 2013. Otsuka continues future discussion with FDA.